Literature DB >> 20005426

Plasminogen activator inhibitor type 1 (PAI-1) is a valuable biomarker for predicting the metabolic syndrome (MS) in institutionalized elderly residents in Taiwan.

Yin-Yi Chou1, Wayne H-H Sheu, Yih-Jing Tang, Yi-Ming Chen, Szu-Chia Liao, Ya-Wen Chuang, Chu-Sheng Lin, Der-Yuan Chen.   

Abstract

Circulating levels of inflammatory and prothrombotic factors are elevated in the metabolic syndrome (MS) and linked with the occurrence of cardiovascular events. The aim of our study was to investigate the relationship between inflammatory and prothrombotic markers and the MS in elderly institutionalized residents. A total of 326 non-diabetic residents of Chuang-Hua Veterans Care Home (age: 79.9+/-4.1 years; 100% males) were enrolled. MS was diagnosed according to the AHA/NHLBI Scientific Statement criteria. Body fat percentage was measured by bioelectrical impedance analysis. Insulin resistance was calculated by homeostasis model assessment for insulin resistance (HOMA-IR). Inflammatory markers, including tumor necrosis factor-a (TNF-alpha), high sensitivity C-reactive protein (hsCRP), and plasminogen activator inhibitor-1 (PAI-1), were determined using ELISA. Elderly residents with the MS had higher systolic and diastolic blood pressures (both p < 0.001) and higher HOMA-IR (p < 0.001), hsCRP (p = 0.008), and PAI-1 levels (p < 0.001) than those without the MS. On multivariate logistic regression analysis, PAI-1 was an independent risk factor for the MS. Of the MS components, elderly residents with higher waist circumferences and higher levels of plasma fasting glucose, and triglyceride (TG), and lower levels of high density lipoprotein (HDL) had higher PAI-1 levels than those without the above components.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20005426     DOI: 10.1016/S0167-4943(09)70012-3

Source DB:  PubMed          Journal:  Arch Gerontol Geriatr        ISSN: 0167-4943            Impact factor:   3.250


  6 in total

1.  The role of PAI-1 and adiponectin on the inflammatory state and energy balance in obese adolescents with metabolic syndrome.

Authors:  Flavia Campos Corgosinho; Aline de Piano; Priscila L Sanches; Raquel M Campos; Patricia L Silva; June Carnier; Lila M Oyama; Lian Tock; Sergio Tufik; Marco T de Mello; Ana R Dâmaso
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

2.  Serum high-sensitivity C-reactive protein as a biomarker in patients with metabolic syndrome: evidence-based study with 7284 subjects.

Authors:  S R Mirhafez; M Ebrahimi; M Saberi Karimian; A Avan; M Tayefi; A Heidari-Bakavoli; M R Parizadeh; M Moohebati; M R Azarpazhooh; H Esmaily; M Nematy; M Safarian; G A Ferns; M Ghayour-Mobarhan
Journal:  Eur J Clin Nutr       Date:  2016-07-27       Impact factor: 4.016

3.  Metabolic syndrome and renal injury.

Authors:  Yi-Jing Sheen; Wayne Huey-Herng Sheu
Journal:  Cardiol Res Pract       Date:  2011-03-13       Impact factor: 1.866

4.  Adipokines (adiponectin and plasminogen activator inhhibitor-1) in metabolic syndrome.

Authors:  M K Garg; M K Dutta; Namita Mahalle
Journal:  Indian J Endocrinol Metab       Date:  2012-01

5.  Comprehensive analysis of circulating adipokines and hsCRP association with cardiovascular disease risk factors and metabolic syndrome in Arabs.

Authors:  Mohamed Abu-Farha; Kazem Behbehani; Naser Elkum
Journal:  Cardiovasc Diabetol       Date:  2014-04-09       Impact factor: 9.951

6.  Frequency of metabolic syndrome and associated factors in institutionalized elderly individuals.

Authors:  Marcia Cristina Sales; Larissa Praça Oliveira; Laura Camila Pereira Liberalino; Aline Tuane Oliveira Cunha; Sara Estefani Soares Sousa; Telma Maria Araujo Moura Lemos; Severina Carla Vieira Cunha Lima; Kenio Costa Lima; Karine Cavalcanti Mauricio Sena-Evangelista; Lucia Fatima Campos Pedrosa
Journal:  Clin Interv Aging       Date:  2018-11-30       Impact factor: 4.458

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.